For generations, people have suffered from brain cancers, neurodegenerative diseases, and metabolic disorders, and most drugs haven’t been optimized to deliver the right amount of dosage to the brain. One reason for that is the blood-brain barrier. That’s why in this episode, we take a look at Bioasis Technologies (TSX.V: BTI) (OTCQB: BIOAF). Their proprietary brain delivery technology, the xB3³ platform, transports medicine across the blood-brain barrier to offer a more successful treatment for diseases of the central nervous system. We take a look at their tech, their stock price and financials. Tune in!
Bioasis Technologies (BTI.V): To Invest or Not?
Latest Articles
- Top 5 Stock Market Gainers and Losers: MCF.V, BRMI.TO, NKE.NE
- Gold to trigger reversal pattern down to $2100?
- Top 5 Stock Market Gainers and Losers: VLE.TO, FANS.TO, FLOW.TO
- Uranium explorers frustrated as good results/Fission buyout fail to lift all boats
- Top 5 Stock Market Gainers and Losers: LGC.V, AMQ.CN, SXTY.CN
Top Searches
Abitibi Greenstone Belt Barrick Gold best canadian cannabis company biotech Bitcoin blockchain bullion California Canada cannabis CBD China Chris Parry covid cryptocurrency DEFN.V FIRE Fraser Institute gambling Gold gold price. gold prices Greg Nolan hemp inflation interest rates investing investments Lukas Kane marijuana mining money Newmont Goldcorp Nexus Gold pharmaceuticals psychedelics resources shrooms stock market stocks technology trading wealth wealth creation weed
by
Leave a Reply